The intrinsic metabolic clearance rate (Cl) and the fraction of the chemical unbound in plasma () serve as important parameters for high-throughput toxicokinetic (TK) models, but experimental data are limited for many chemicals. Open-source quantitative structure-activity relationship (QSAR) models for both parameters were developed to offer reliable predictions for a diverse set of chemicals regulated under the U.S. law, including pharmaceuticals, pesticides, and industrial chemicals. As a case study to demonstrate their utility, model predictions served as inputs to the TK component of a risk-based prioritization approach based on bioactivity/exposure ratios (BERs), in which a BER < 1 indicates that exposures are predicted to exceed a biological activity threshold. When applied to a subset of the Tox21 screening library (6484 chemicals), we found that the proportion of chemicals with BER <1 was similar using either (1133/6484; 17.5%) or (148/848; 17.5%) parameters. Further, when considering only the chemicals in the Tox21 set with data, there was a high concordance of chemicals classified with either BER <1 or >1 using either or parameters (767/848, 90.4%). Thus, the presented QSARs may be suitable for prioritizing the risk posed by many chemicals for which measured TK data are lacking.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548983 | PMC |
http://dx.doi.org/10.1021/acs.est.0c06117 | DOI Listing |
Stat Med
February 2025
Department of Mathematical Sciences, The University of Texas at Dallas, Richardson, Texas.
Advances in next-generation sequencing technology have enabled the high-throughput profiling of metagenomes and accelerated microbiome studies. Recently, there has been a rise in quantitative studies that aim to decipher the microbiome co-occurrence network and its underlying community structure based on metagenomic sequence data. Uncovering the complex microbiome community structure is essential to understanding the role of the microbiome in disease progression and susceptibility.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Drug Safety Research and Development, Pfizer Research & Development, Pearl River, NY 10965, USA.
: Respiratory syncytial virus (RSV) infections usually cause mild, cold-like symptoms in most people, but are a leading infectious disease causing infant death and hospitalization and can result in increased morbidity and mortality in older adults and at-risk individuals. Pfizer has developed Abrysvo, an unadjuvanted bivalent recombinant protein subunit vaccine containing prefusion-stabilized fusion (F) proteins representing RSV A and RSV B subgroups (RSVpreF). It is the only RSV vaccine approved for both maternal immunization to protect infants and active immunization of older adults (≥60 years) and 18-59-year-old individuals with high-risk conditions for prevention of RSV disease.
View Article and Find Full Text PDFPol J Pathol
January 2025
Karadeniz Technical University, Faculty of Medicine, Department of Pathology, Trabzon, Turkey.
The enzyme phosphatidylinositide-3-kinase (PI3K) regulates cellular proliferation and apoptosis. Somatic mutations in the PIK3CA gene can accelerate these processes and significantly contribute to the development and progression of breast cancer. This study aimed to ascertain the PIK3CA gene mutations in breast cancer patients and investigate their correlation with certain clinicopathological characteristics.
View Article and Find Full Text PDFBioorg Chem
January 2025
Institute of Reproductive Medicine, Medical School, Nantong University, Nantong, Jiangsu 226001, China; School of Pharmacy, Naval Medical University, Shanghai 200433, China. Electronic address:
Polydatin (PD), a glucoside derivative of resveratrol (RES), is extracted as a monomer compound from the dried rhizome of Polygonum cuspidatum. Our laboratory synthesized PD via the biotransformation of resveratrol. To assess the reproductive protective effects of PD, an oligozoospermia mouse model was induced by administering 30 mg/kg busulfan (BUS) via intraperitoneal injection.
View Article and Find Full Text PDFBiotechnol Prog
January 2025
Purification Development, Genentech, South San Francisco, California, USA.
Platforms have long been implemented for downstream process development of monoclonal antibodies (mAbs) to streamline development and reduce timelines. These platforms are also increasingly being used for other complex biologics modalities. While development has traditionally been conducted at the lab bench scale in a sequential manner, automated miniaturized and parallelized approaches like RoboColumns and resin plates have also been implemented for chromatographic screening.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!